Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

ClinicalTrials.gov ID: NCT05883449

Public ClinicalTrials.gov record NCT05883449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.

Study identification

NCT ID: NCT05883449
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Affimed GmbH; Industry
Enrollment: 25 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 10, 2023 (Actual)
Primary completion: Nov 7, 2024 (Actual)
Completion: Jun 13, 2025 (Actual)
Last update posted: Aug 20, 2025

2023 – 2025

United States locations

U.S. sites: 15
U.S. states: 13
U.S. cities: 14

Facility	City	State	ZIP	Site status
O'Neal Comprehensive Cancer Center at UAB	Birmingham	Alabama	35294	—
City of Hope National Medical Center	Duarte	California	91010	—
UC Irvine Health	Orange	California	92868	—
Sarah Cannon Research Institute	Denver	Colorado	80218	—
Norton Cancer Institute	Louisville	Kentucky	40207	—
Beth Israel Deaconess Medical	Boston	Massachusetts	02215	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota	55455	—
Washington University School of Medicine	St Louis	Missouri	63110	—
John Theurer Cancer Center	Hackensack	New Jersey	07601	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
UNC Immunotherapy Team, University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
Cleveland Clinic	Cleveland	Ohio	44195	—
University of Pennsylvania, Abramson Cancer Center	Philadelphia	Pennsylvania	19104	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05883449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2025 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05883449 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →